Alkermes (ALKS) EBIT Growth (3y) (2013 - 2026)
Alkermes (ALKS) EBIT Growth (3y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | 29.31% |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | 4.24% |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | 0.90% |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 1.82% |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | -74.25% |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 27.21% |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 35.42% |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | - |
| 10 | Alkermes | 8.02 Bn | 7.37 Bn | 397.90 Mn | -59.74% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -59.74% |
| Mar 31, 2026 | -63.87% |
| Dec 31, 2025 | -20.49% |
| Sep 30, 2025 | 51.38% |
| Jun 30, 2025 | 67.49% |
| Mar 31, 2025 | 36.06% |
| Dec 31, 2024 | 7.93% |
| Sep 30, 2024 | 94.24% |
| Jun 30, 2024 | 191.83% |
| Mar 31, 2024 | 66.74% |
| Dec 31, 2023 | 55.75% |
| Sep 30, 2023 | 118.01% |
| Jun 30, 2023 | 117.97% |
| Mar 31, 2023 | 33.54% |
| Dec 31, 2022 | 138.91% |
| Sep 30, 2022 | -4.19% |
| Jun 30, 2022 | 1.38% |
| Mar 31, 2022 | 29.54% |
| Dec 31, 2021 | 1,763.46% |
| Sep 30, 2021 | 19.12% |